GlassScriptPhysician profile
Julia Gopstein
NPI 1831728153
$3,597.57
in general payments reported to CMS, 2019-2025
27 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $818 · 2024: $1,206 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,571 · Education: $26.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,570.94 |
| Education | $26.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.01 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.74 | 2023-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $283.46 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $242.23 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $240.88 | 2023-2025 | |
| Ardelyx, INC. | $185.70 | 2024-2025 | Ibsrela |
| Pfizer INC. | $184.52 | 2023-2024 | |
| Madrigal Pharmaceuticals | $177.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $174.59 | 2024-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $162.87 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $97.24 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $68.65 | 2023-2024 | Rebyota |
| Exact Sciences Corporation | $67.39 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $54.14 | 2023-2025 | Vowst |
| Laborie Medical Technologies Corp. | $40.41 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $34.79 | 2024-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $34.10 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $32.14 | 2023 | Idacio |
| Ironwood Pharmaceuticals, INC | $20.44 | 2024 | |
| Amgen INC. | $18.91 | 2025 | Uplizna |
| Merck Sharp & Dohme LLC | $18.69 | 2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $17.86 | 2023 | |
| Celltrion USA INC. | $16.98 | 2024 | Zymfentra |
| Celgene Corporation | $15.76 | 2023 | Zeposia |
| Novo Nordisk INC | $15.54 | 2023 | Wegovy |
| Intercept Pharmaceuticals, INC. | $14.85 | 2023 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $13.57 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Gopstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.